호흡기계 작용 약물의 치료군 중복처방 평가기준 개발

• Published in: Yaghag-hoi-ji Vol. 56; no. 2; pp. 126 - 135
• Main Authors: 최경업(Kyung Eob Choi), 손현순(Hyun Soon Sohn), 김남효(Nam Hyo Kim), 신현택(Hyun Taek Shin), 이영숙(Young Sook Lee)
• Format: Journal Article
• Language: Korean
• Published: The Pharmaceutical Society Of Korea 30.04.2012; 대한약학회
• Subjects: 약학; DUR; mucolytics; antihistamines; therapeutic duplication; cough suppressants; respiratory drugs
• ISSN: 0377-9556; 2383-9457

Purpose: To develop therapeutic duplication criteria for the drugs used for respiratory diseases. Method: Therapeutic duplication was defined as "more than 2 drug ingredient-usage in which each has the same therapeutic effect and combination therapy does not confer additional therapeutic benefit". Respiratory system drugs approved in Korea were examined for the study. The WHO's Anatomical Therapeutic Chemical Classification System was used for grouping of the corresponding drug ingredients. The principles and recommendations on combination usage or multiple drug regimens were reviewed by using the clinical practice guidelines, textbooks, product labelings, and clinical articles. Clinical expert group consultation was performed and expert opinions were incorporated into the final criteria. Results: Nine hundred sixty two drug products with Korean Food and Drug Administration classification codes of 141, 149, 222, and 229 were evaluated, of which 87 active ingredients were composed. The drug ingredients were classified into 12 groups (antihistamines, oral nasal decongestants, leukotriene receptor antagonists, inhaled anticholinergics, inhaled corticosteroids, oral ${\beta}2$-agonists, long-acting ${\beta}2$-agonists, short-acting ${\beta}2$-agonists, xanthines, antiallergics, mucolytics and cough suppressants). The use of more than 2 drug ingredients including the same group was therapeutic duplication, and thus combination should be recommended not to be used. Conclusion: Twelve drug groups were identified as therapeutic duplication criteria. Combination therapy within each group should not be used otherwise therapeutic benefits outweigh potential risks.